India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, mitochondrial function is enhanced by 30-60 percent. “Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation,” Ram Mukunda, CEO of IGC, stated in the news release. “The initial commercialization will be through licensed medical cannabis dispensaries.” As noted in this morning’s update, mitochondrial dysfunction is believed to be at the apex of the Alzheimer’s pyramid, making it responsible for triggering a cascade of symptoms resulting in the devastating condition. As such, IGC-AD1’s ability to improve mitochondrial function could serve as a significant breakthrough in the treatment of Alzheimer’s, which is noted as America’s most expensive disease with its estimated annual cost of $236 billion.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More